RPL28 and neoplasm: Notably, no significant changes were observed in MHC-I and PD-L1 expression following RPL28 knockdown.<h4>Conclusions</h4>Our findings demonstrate that RPL28 contributes to sorafenib resistance in HCC by upregulating CDC6, contributing to tumor proliferation and drug resistance.